Introduction

40
Prostate cancer (PCa) is the most prevalent cancer type among men and the second leading cause 41 of male cancer-associated deaths in the United States accounting for an estimated 165,000 new cases survival are still measured in months [2, 3] .
48
PCa screening and disease control is largely based on the prostate specific antigen (PSA) test that 49 was initially introduced as a follow-up instrument for the detection of recurrence and progression to 50 metastatic disease. Subsequently, its potential as an early diagnostic tool was explored [4, 5] and PSA 51 was accepted as a standard test to identify men at risk of PCa before any symptoms appeared. Thus,
52
PSA was heralded as a promising early detection biomarker [5] . However, PSA screening has been 53 considered a controversial assessment since many men are over-diagnosed and over-treated since PSA
54
is not capable of differentiating more indolent from aggressive disease. It is estimated that 23% to 60% 55 of men, with increased PSA levels present with prostate tumors that would remain clinically 56 insignificant during their lifetime [6] . Unfortunately, these men who present with increased PSA may 57 be submitted to unnecessary aggressive and invasive treatment and its consequent comorbidities [6] [7] [8] 58 [6] [7] [8] . The use of active surveillance programs in men who are considered to have very low and low risk 59 prostate cancer has had a major impact on over-treatment but one of the major dilemmas in PCa
60
remains to identify patients with aggressive tumors at an early stage so that they can benefit from 61 immediate definitive treatment. PSA based tests such as the Prostate Health Index (phi) and the 4K 62 Score, are options to predict more accurately detect PCa [9] . The first test, that measures total, free and
63
[-2]proPSA [10] ; is FDA approved and have shown to be an important tool for risk stratification [11, 12] .
64
The 4K Score measures four kallikrein markers (total, free and intact PSA and hK2) and presents the 65 same performance and is also associated with the risk of MPCa [13, 14] . Still, additional molecular 66 biomarkers for a combined test are crucial to categorize tumors according to their aggressive potential 67 in a more accurate manner and to stratify men with PCa into more appropriate treatment strategies.
68
Cancer/testis antigens (CTAs) constitute an important class of cancer biomarkers that have not 
78
aggressive PCa. However, since it was a retrospective study, the possibility of using these CTAs as 79 predictors for MPCa could not be assessed.
80
In this study, we used the data generated by Takahashi et 
114
The paired normal and PCa samples for immunohistochemistry assays were included in tissue 115 microarrays (TMAs). The two TMAs included 80 unique prostate cancer patients representing different
116
Gleason scores (3+3, 3+4, 4+3, and ≥8) with quadruplicates of cancer and cancer-adjacent normal areas.
117
The detailed demographics of the total 80 cases stratified by Gleason scores are shown in 118 
Supplementary
156
given as the total brown pixel count for that region. The frequency (area of positive staining) is given by 157 the ratio of positive brown region and the total area selected for analysis (positive + negative area).
158
Protein expression differences between the paired normal and tumor areas were compared using the
159
Wilcoxon matched-pairs test. The average for all cores available from each patient for qIHC analysis
160
was calculated, and the values were used to compare medians between the groups (tumor vs. benign).
161
Protein expression (frequency or intensity) was considered significantly different for a P value ≤0.05.
162
Statistical analysis
163
Receiver Operator Characteristic (ROC) curves were used to identify CTAs with a high probability
164
of accurately discriminating between localized and metastatic PCa or tumor and non-tumor cases. Gene 165 expression changes were considered significant when AUC>0.7. Wilcoxon signed-rank or Mann-
166
Whitney non-parametric test were used to compare CTA gene expression means between LPCa vs.
167
MPCa and benign vs. tumor tissues, respectively. Gene expression differences were considered 168 significant when P value ≤0.05. After the best individual genes were identified, the multivariate logistic 
173
Differential CTA gene expression in LPCa and MPCa
174
Nanostring is a digital multiplex approach in which multiple mRNAs can be absolutely quantified qRT-PCR was used to verify the results obtained using the Nanostring multiplex approach.
199
Validation was performed for all 22 CTAs using the same sample sets that were examined by Takahashi   200 et al [25] . Statistical analysis showed significant ROC curves (AUC>0.7) ( Table 1) 
217
Gene expression analysis of the 22 paired tumor and normal samples did not show significant 218 differences for CEP55, NUF2, PBK, RQCD1 and TTK (Figure 2) 
231
CTAs no significant changes in expression was noted.
232 Table 2 -ROC analysis for gene expression profile of paired normal and tumor samples. 
258
319
One of the main causes of death among men with PCa is metastatic disease [1] . Although PSA is 320 the gold standard for screening, it lacks the ability to predict the development of metastasis [29, 30] .
321
Since the CTAs we selected from the Takahashi 
333
An important contribution of this study is that we show the importance of using a panel of 
344
suggesting that this gene is critical for tumor development but not for the metastasis establishment in a 345 distant sites. This assumption is corroborated by the fact that PAGE4 protein expression is 346 downregulated in metastatic PCa suggesting that PAGE4 may actually be a metastasis suppressor [38] .
347
Recent studies suggest that PAGE4 is developmentally regulated with dynamic expression 348 patterns in the fetal prostate and that it is also a stress-response protein that is up-regulated in response 349 to cellular stress [38] . In the present study, we observed loss of expression of PAGE4 in in MPCa cases. 
377
The authors also showed that circulating tumor cells expressing the correspondent gene could only be 378 detected in peripheral blood of PCa patients, while undetectable in healthy men [47] .
379
One intriguing observation in our study is that the gene expression levels of PAGE4, NUF2 and
380
SPAG4 are increased in normal prostate tissue relative to the tumor samples. Since the normal tissues 381 were collected adjacent to the prostate tumors it is probable that the up-regulation of CTAs in non-382 cancer areas is a field effect as previously described by Zeng et al. [48] . They describe the same trend for
383
PAGE4 when comparing its expression in PCa with the adjacent normal tissue from the same patients.
384
Another plausible reason for the discrepancy in gene expression in the paired tumor and normal 385 samples is that the RNA abundancy for these genes does not reflect protein levels, since our IHC results
386
show that PAGE4, NUF2 and SPAG4 are up-regulated in tumor although the mRNAs are down-387 regulated when compared to the normal prostate. This would also explain why for the other CTAs no 388 differences in mRNA levels in normal and tumor contrast with significant differences at the protein 
